Anjali Reth, head of the Association of Young Surgeons of Germany, visited our University on May 31st with a lecture on the features of the postgraduate training of surgeons in her country.
Despite the necessary exams for studying in Germany, a...
Hunter syndrome (mucopolysaccharidosis type II) is a recessive X-linked disorder due to mutations in the iduronate 2-sulfatase (IDS) gene encoding a lysosomal iduronate 2-sulfatase.
First Study of prevalence and risk factors for abdominal wall hernia in the Central Russian population
Medical history of 10 > years was taken and clinical examination was performed for residents of Kryukovo rural community (Central Russia). Abdominal wall hernias have been found in 20.9% of population, including 298 men and 485 women (mean age 49.3).
Study of natalizumab treatment of multiple sclerosis in Russia
Natalizumab (NTZ) is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program.
Professors Ana Bianchi and Ola Saugstad visited to our University
On May 20, Professor Ana Bianchi (Montevideo, Uruguay), an internationally recognized expert in the field of ultrasound in obstetrics, gynecology and perinatal medicine, as well as an outstanding neonatologist Ola Didrik Saugstad (Oslo, Norway) gave...
Win on the International Olympiad in Surgery and Topographic Anatomy
Our students have become winners of the International Olympiad in Surgery and Topographic Anatomy at Vitebsk State Medical University (Belarus). Our students of the 3rd and 4th courses competed on an equal footing with students of the 5th and 6th courses...
Professor Mark Graber from the Department of Emergency and Family Medicine of the University of Iowa (USA), a member of the Academy of Emergency Medical Aid at the American Association of Family Physicians, read three lectures ("Diabetes 2019", "Done CHF...
Participation in randomised, open-label, phase 3 trial of the combination for treatment of multiple myeloma
Pirogov Medical University has took a part in the international randomised, open-label, phase 3 trial of the combination of pomalidomide, bortezomib, and dexamethasone for treatment of multiple myeloma.
